Anxiety reduction during atomoxetine and methylphenidate medication in children with ADHD.

Anxiety reduction during atomoxetine and methylphenidate medication in children with ADHD.

Pediatr Int. 2015 Nov 18;

Authors: Eva S, Veronika MH, Igor H, Tomas K, Igor O, Gabriela N

Abstract
BACKGROUND: Atomoxetine and methylphenidate are widely used to treat ADHD with similar effectiveness after 8 weeks of treatment, by which atomoxetine can develop its full effect. Both drugs have been shown to have also an effect on comorbid anxiety. To our best knowledge, no study has compared their effect on the dynamics of the anxiety symptoms reduction. The aim of this study was to compare the medication effect on core and comorbid anxiety symptoms dynamics in children with ADHD.
METHODS: Sixty-nine patients participated in the study, 36 patients were taking atomoxetine and 33 patients methylphenidate. Therapeutic effect on core symptoms of ADHD were measured by ADHD-rating scale IV, symptoms of anxiety were measured by Conner’s Parent Rating Scale. Symptoms were measured prior to and every 2 weeks during 8 weeks of treatment.
RESULTS: We found significant decrease in anxiety subscale score of CPRS in both medication groups. Anxiety subscale score was significantly lower in atomoxetine group in the fourth week lasting until the eight week of medication.
CONCLUSION: Both atomoxetine and methylphenidate reduced the symptoms of ADHD and anxiety. Atomoxetine was more effective in anxiety symptoms reduction from the fourth week of treatment. This article is protected by copyright. All rights reserved.

PMID: 26579704 [PubMed – as supplied by publisher]

via http://www.ncbi.nlm.nih.gov/pubmed/26579704?dopt=Abstract